​

Biohaven (BHVN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BHVN Stock Forecast

Biohaven (BHVN) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $59.33, with a high of $61.00 and a low of $57.00. This represents a 191.26% increase from the last price of $20.37.

$20 $29 $38 $47 $56 $65 High: $61 Avg: $59.33 Low: $57 Last Closed Price: $20.37

BHVN Stock Rating

Biohaven stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (94.44%), 1 Hold (5.56%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 1 17 0 Strong Sell Sell Hold Buy Strong Buy

BHVN Price Target Upside V Benchmarks

TypeNameUpside
StockBiohaven191.26%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts1215
Avg Price Target$60.00$58.50$59.87
Last Closing Price$20.37$20.37$20.37
Upside/Downside194.55%187.19%193.91%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25511---16
Mar, 25511---16
Feb, 25510---15
Jan, 25510---15
Dec, 24510---15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 20, 2025Deutsche Bank$60.00$28.18112.92%194.55%
Mar 04, 2025Bernstein$57.00$31.3781.70%179.82%
Dec 04, 2024Leonid TimashevRBC Capital$61.00$46.5830.96%199.46%
Oct 15, 2024Jason GerberryBank of America Securities$65.00$52.7723.18%219.10%
Sep 24, 2024Marc GoodmanLeerink Partners$60.00$44.2235.69%194.55%
Sep 24, 2024Douglas TsaoH.C. Wainwright$59.00$45.9428.43%189.64%
Sep 24, 2024Jason GerberryBank of America Securities$62.00$45.9434.96%204.37%
Sep 24, 2024Leonid TimashevRBC Capital$68.00$45.9448.02%233.82%
Sep 23, 2024Thomas ShraderBTIG$59.00$46.5626.72%189.64%
Sep 23, 2024Brian SkorneyRobert W. Baird$60.00$46.5628.87%194.55%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 20, 2025Deutsche BankBuyBuyhold
Dec 04, 2024RBC CapitalOutperformOutperformhold
Nov 13, 2024Cowen & Co.BuyBuyhold
Oct 15, 2024Bank of America SecuritiesBuyBuyhold
Sep 24, 2024Leerink PartnersOutperformOutperformhold
Sep 24, 2024BernsteinOutperformOutperformhold
Sep 24, 2024H.C. WainwrightBuyBuyhold
Sep 24, 2024Bank of America SecuritiesBuyBuyhold
Sep 24, 2024RBC CapitalOutperformOutperformhold
Sep 23, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-25 $-20 $-15 $-10 $-5 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.97$-12.75$-5.73$-9.28----
Avg Forecast$-7.31$-9.79$-5.22$-9.01$-6.36$-5.57$-4.11$-1.78
High Forecast$-5.85$-0.41$-5.00$-8.11$-5.49$-3.72$-1.29$-0.08
Low Forecast$-8.77$-22.52$-5.45$-9.94$-7.27$-7.15$-6.30$-4.10
Surprise %-18.33%30.23%9.77%3.00%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$462.51M-------
Avg Forecast$426.10M$820.28M-$7.69M$18.54M$154.46M$501.96M$898.51M
High Forecast$511.32M$984.33M-$15.39M$37.10M$309.07M$510.22M$1.80B
Low Forecast$340.88M$656.22M-$2.03M$4.88M$40.67M$493.70M$236.60M
Surprise %8.54%-------

Net Income Forecast

$-850M $-680M $-510M $-340M $-170M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-213.80M$-570.28M$-408.17M$-846.42M----
Avg Forecast$-596.80M$-620.81M$-408.17M$-642.41M$-454.23M$-386.92M$-270.35M$-126.97M
High Forecast$-477.44M$-496.65M$-326.53M$-577.16M$-391.03M$-265.06M$-91.93M$-5.37M
Low Forecast$-716.16M$-744.97M$-489.80M$-707.67M$-517.43M$-508.79M$-448.78M$-292.19M
Surprise %-64.18%-8.14%-31.76%----

BHVN Forecast FAQ

Is Biohaven stock a buy?

Biohaven stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Biohaven is a favorable investment for most analysts.

What is Biohaven's price target?

Biohaven's price target, set by 18 Wall Street analysts, averages $59.33 over the next 12 months. The price target range spans from $57 at the low end to $61 at the high end, suggesting a potential 191.26% change from the previous closing price of $20.37.

How does Biohaven stock forecast compare to its benchmarks?

Biohaven's stock forecast shows a 191.26% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Biohaven over the past three months?

  • April 2025: 31.25% Strong Buy, 68.75% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 31.25% Strong Buy, 68.75% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Biohaven’s EPS forecast?

Biohaven's average annual EPS forecast for its fiscal year ending in December 2025 is $-6.36, marking a -31.47% decrease from the reported $-9.28 in 2024. Estimates for the following years are $-5.57 in 2026, $-4.11 in 2027, and $-1.78 in 2028.

What is Biohaven’s revenue forecast?

Biohaven's average annual revenue forecast for its fiscal year ending in December 2025 is $18.54M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $154.46M, followed by $501.96M for 2027, and $898.51M for 2028.

What is Biohaven’s net income forecast?

Biohaven's net income forecast for the fiscal year ending in December 2025 stands at $-454M, representing a -46.34% decrease from the reported $-846M in 2024. Projections indicate $-387M in 2026, $-270M in 2027, and $-127M in 2028.